NCT00924807View on ClinicalTrials.gov

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide acetate, Bicalutamide, Sorafenib

Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg

Trial Locations (1)

10019

St.Luke's-Roosevelt Hospital Center, New York

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Beth Israel Medical Center

OTHER

NCT00924807 - Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | Biotech Hunter | Biotech Hunter